Psilocybin, the active ingredient in magic mushrooms, has a long history of ceremonial use by indigenous peoples and is now being studied in Western medicine for treating existential distress in cancer patients. Palliative care has improved management of physical symptoms, but psychospiritual suffering remains difficult to treat with conventional methods. Early research on psychedelic therapies targeted the existential suffering that often accompanies dying, offering a potential new approach to healing in the context of end-of-life care.
Psilocybin-assisted psychotherapy, using psilocybin-containing mushrooms or synthetic psilocybin within a therapeutic mindset and environment, may safely and effectively reduce demoralization, death anxiety, and existential distress in patients with serious illness. A case series of advanced cancer patients in Montreal, Canada, who received physician-supervised home-based treatment suggests safety and efficacy. This work, performed outside clinical trials in Quebec's public healthcare system, aimed to provide equitable access and a more patient-centric, culturally-informed approach. However, societal discrimination and stigma, including from healthcare professionals, remain barriers to equitable care, which the authors discuss along with potential solutions.